European Companies Search Engine
Abbvie Inc., North Chicago, United States
Watch
If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.
Dossier
The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .
Add to dossier (if available):
Name
Abbvie Inc.
Register
Sirul
Siren 831321427
Sirul
Siret 83132142700013
Stockp
ABBV
Stockp
ABBV.BA
Address
Corporate purpose
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Additional info
2834
Pharmaceutical Preparations
History
Network
Loading network
Publications
9 Apr 2024
9 Apr 2024
31 Dec 2023
in
France
14 Dec 2023
14 Dec 2023
14 Dec 2023
2 Jun 2023
in
France
31 Dec 2022
in
France
Year 2022
in
Euipods
31 Dec 2021
in
France
14 Dec 2021
Year 2021
in
Euipotm
31 Dec 2020
in
France
Year 2020
in
Euipods
Year 2020
in
Euipotm
Year 2020
in
Epobase
31 Dec 2019
in
France
Year 2019
in
Euipods
Year 2019
in
Epobase
Year 2019
in
Hor
31 Dec 2018
in
France
Year 2018
in
Euipods
1 Nov 2018
in
Hor
1 Sept 2018
in
Hor
1 Sept 2018
in
Hor
31 Dec 2017
in
France
Year 2017
in
Euipods
5 Oct 2017
1 Aug 2017
1 Aug 2017
31 Dec 2016
in
France
1 Sept 2016
in
Hor
Year 2016
in
Euipods
31 Dec 2015
in
France
Year 2015
in
Epobase
17 Nov 2015
31 Dec 2014
in
France
Year 2014
in
Epobase
31 Dec 2013
in
France
31 Dec 2012
in
France
Year 2012
in
Epobase
31 Dec 2011
in
France
Year 2011
in
Epobase
14 Jun 2011
31 Dec 2010
in
France
Year 2010
in
Epobase
31 Dec 2009
in
France
Year 2009
in
Epobase
Year 2008
in
Euipotm
Year 2007
in
Epobase
Year 2006
in
Epobase
14 Dec 2006
14 Dec 2006
Mentions
The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.
The visualizations for "Abbvie Inc., North Chicago, United States"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
